EQS Group-News: Relief Therapeutics Holdings AG / Key word(s): Personnel
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
Raghuram (Ram) Selvaraju, Chairman of the Board, said: "We are delighted to have Jack join the Relief team. His broad expertise will be invaluable to the Company at a time when RLF-100TM outpaces traditional clinical development timelines to meet the necessary requirements to demonstrate safety and efficacy data in the treatment of severely ill COVID-19 patients. His regulatory and public company experience will be critical in our intensive interactions with regulatory authorities and our increasing dialogue with the investment community in order to raise awareness and understanding of Relief. I very much look forward to working with him."
"I am impressed by how swiftly Relief reacted to one of the largest healthcare disasters of our time by rapidly advancing their proprietary asset into clinical development and towards approval. I am excited to join the Company at a stage when it is evolving and growing to meet a major unmet medical need with a potentially lifesaving treatment for severely sick COVID-19 patients," said Jack Weinstein, Chief Financial Officer and Treasurer. "I look forward to leveraging my established industry know-how and network to help steward Relief into this new, exciting stage in its development and to be part of the Relief team to help realize its long- term strategic plans beyond the planned commercialization of RLF-100TM worldwide."
Relief also reported that Jeremy Meinen will maintain his current role and responsibilities within the Company as principal finance and accounting officer and will take up the new title of Vice President of Finance and Administration with immediate effect.
In addition, Yves Sagot, Ph.D., co-founder and former Chief Scientific Officer, has as of today transitioned into a temporary consulting role. This change will allow him to continue to advise Relief on its R&D activities as the Company rapidly advances RLF-100(TM) in development, while allowing him to take on new opportunities.
Raghuram (Ram) Selvaraju commented: "We are extremely grateful for Yves' contributions to Relief throughout its history, in particular his understanding of the potential RLF-100TM may hold in the treatment of severe COVID-19 patients. We are pleased he will continue to serve the Company in a short-term consulting capacity and wish him the best in his future endeavors."
Relief holds orphan drug designations from the U.S. FDA and the European Union for the use of RLF-100TM to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a patent issued in the United States and various other countries covering potential formulations of RLF-100TM.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
End of Media Release
FOR MEDIA/INVESTOR INQUIRES:
FOR MEDIA/INVESTOR INQUIRES:
Relief Therapeutics Holdings AG
Avenue de Sécheron 15
SIX Swiss Exchange
EQS News ID:
End of News
EQS Group News Service